GH Research Shareholders Approve Director Slate and 2026 Auditor at June AGM
I'm LongbridgeAI, I can summarize articles.GH Research shareholders approved the director slate and reappointed PricewaterhouseCoopers Ireland as auditor for 2026 at the June AGM. This reinforces governance continuity. Analysts rate the stock a Buy with a $65 target, while TipRanks' AI suggests Neutral due to weak financials despite supportive technicals.
GH Research ( (GHRS) ) just unveiled an announcement.
On June 25, 2026, GH Research PLC held its annual general meeting, where shareholders approved all board-recommended resolutions, including the re-election of directors Florian Schönharting, Michael Forer, Dermot Hanley and Duncan Moore. The meeting also saw investors ratify PricewaterhouseCoopers Ireland as the company’s independent auditor for the 2026 financial year, reinforcing continuity in governance and oversight for stakeholders.
These approvals secure leadership stability at GH Research, signaling shareholder support for the current strategic direction and corporate governance framework. The reappointment of PwC sustains audit consistency through the end of 2026, which may reassure investors about financial reporting quality and regulatory compliance as the company navigates its next phase of development.
The most recent analyst rating on (GHRS) stock is a Buy
with a $65.00 price target.
To see the full list of analyst forecasts on GH Research stock,
see the GHRS Stock Forecast page.
Spark’s Take on GHRS Stock
According to Spark, TipRanks’ AI Analyst, GHRS is a Neutral.
The score is held down primarily by weak financial performance—no revenue, widening losses, and sustained cash burn—despite a strong low-debt balance sheet. Technicals are supportive with price above key moving averages and positive momentum, but valuation remains challenged due to losses (negative P/E) and no dividend data.
To see Spark’s full report on GHRS stock,
click here.
More about GH Research
GH Research PLC is an Ireland-based foreign private issuer listed in the United States, operating within the life sciences and biotech investment space. The company is governed by a board of directors and adheres to international reporting standards, reflecting its focus on global capital markets and compliance with cross-border securities regulation.
Average Trading Volume: 245,080
Technical Sentiment Signal: Buy
Current Market Cap: $1.74B
For a thorough assessment of GHRS stock, go to TipRanks’ Stock Analysis page.